Iveric Bio, a biopharmaceutical company focused on the discovery and development of treatments for human retinal diseases, entered into a sponsored research agreement with Drs. Karina Guziewicz and William Beltran, both from the Penn School of Veterinary Medicine to examine the efficacy and toxicity of a novel treatment for inherited retinal diseases (IRDs) associated with mutations of the BEST1 gene (i.e., bestrophinopathies), in a preclinical canine model of the disease. It’s estimated that in the U.S. and EU combined, there are approximately 10,000 to 40,000 currently suffering from BEST1-related IRDs.
